Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Varsha Gandhi, PhD, on Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Nov
14
Today In Oncology
FDA Approves Ziftomenib for NPM1-Positive AML
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
Ezabenlimab, Induction Chemotherapy, and Adaptive Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma
Transfusion Access Prioritized Over Routine Hospice Services Among Patients With Blood Cancers
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo